A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of AC0058TA in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
At a glance
- Drugs AC 0058TA (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors ACEA Biosciences
- 14 Jun 2017 Results presented in an ACEA Biosciences media release.
- 24 Apr 2017 Status changed from recruiting to completed.
- 16 Aug 2016 New trial record